Treatment of neuropsychiatric syndromes in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 5, Issue 3, 2005, Pages 413-420

  Patten, Scott B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cognitive disorders; Depressive disorders; Fatigue; Multiple sclerosis; Sexual disorders

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DESIPRAMINE; DONEPEZIL; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PEMOLINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPASMOLYTIC AGENT;

ADJUSTMENT DISORDER; ANOREXIA; ANXIETY DISORDER; COGNITIVE DEFECT; COGNITIVE THERAPY; DELIRIUM; DELUSIONAL DISORDER; DYSTONIA; EUPHORIA; FATIGUE; HUMAN; HYPOMANIA; IRRITABILITY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MOOD DISORDER; MULTIPLE SCLEROSIS; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STROKE; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN;

DEPRESSIVE DISORDER, MAJOR; FATIGUE; HUMANS; MENTAL DISORDERS; MULTIPLE SCLEROSIS; PSYCHOTROPIC DRUGS; SLEEP DISORDERS; SYNDROME;

EID: 18944397950     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.3.413     Document Type: Review

References (56)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TB). American Psychiatric Association, Washington, DC, USA (2000).
2. Katon WJ, Von Korff M, Lin EHB et al. The Pathways study. Arch. Gen. Psychiatry 61, 1042-1049 (2004).
3. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorders and multiple sclerosis. Arch. Neurol. 44, 376-378 (1987).
4. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen. Hosp. Psychiatry 9, 426-434 (1987).
5. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult. Scler. 6, 115-120 (2000).
6. Patten SB, Beck CA, Williams JVA, Barbui C, Metz L. Major depression in multiple sclerosis: a population-based perspective. Neurology 61, 1524-1527 (2003).
7. Aikens JE, Reinecke MA, Pliskin NH et al. Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Derpession Inventory? J. Behav. Med. 22, 127-141 (1999).
8. Nyenhuis DL, Rao SM, Zajecka JM et al. Mood disturbance versus other symptoms of depression in multiple sclerosis. J. Internatl Neuropsychol. Soc. 1, 291-296 (1995).
9. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am. J. Psychiatry 147, 1493-7 (1990).
10. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Cons. Clin. Psychol. 69, 942-949 (2001).
11. Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carrol scale. Neurol. Res. 17, 421-422 (1995).
12. Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J. Neuropsych. Clin. Neurosci. 11, 271-273 (1999).
13. Stenager EN, Stenager E, Koch-Henriksen N et al. Suicide and multiple sclerosis: an epidemiological investigation. J. Neurol. Neurosurg. Psychiatry 55, 542-545 (1992).
14. Marrs RW. A meta-analysis of bibliotherapy studies. Am. J. Comm. Psychol. 23, 843-870 (1995).
15. Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. BMJ 328, 265 (2004).
16. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin. Pharm. Ther. 13, 694-698 (1972).
17. Fishman SM, Catarau EM, Sachs GM, Stojanovic M, Borsook D. Corticosteroid-induced mania after single regional application at the celiac plexus. Anesthiology 85, 1194-1196 (1996).
18. Vincent FM. The neuropsychiatric complications of corticosteroid therapy. Comp. Ther. 21, 524-528 (1995).
19. Rundell JR, Wise MG. Causes of organic mood disorder. J. Neuropsychiatry Clin. Neurosci. 1, 398-400 (1989).
20. Waraich PS, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can. J. Psychiatry 49, 124-38 (2004).
21. Feinstein A, Feinstein K. Depression associated with multiple sclerosis - looking beyond diagnosis to symptom expression. J. Affect. Disord. 66, 193-198 (2001).
22. Finger S. A happy state of mind. A history of mild elation, denial of disability, optimism, and laughing in multiple sclerosis. Arch. Neurol. 55, 241-250 (1998).
23. Feinstein A. Clinical Neuropsychiatry of Multiple Sclerosis. Cambridge University Press, UK (1999).
24. Feinstein A, Feinstein K, Gray T, O'Connor P. The prevalence and neurobehavioural correlates of pathological laughter and crying in multiple sclerosis. Arch. Neurol. 54, 1116-1121 (1997).
25. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. N. Engl. J. Med. 312, 1480-1482 (1985).
26. Udaka F, Yameo S, Nagata H, Nakamura S, Kameyama M. Pathological laughing and crying treated with levodopa. Arch. Neurol. 41, 1095-1096 (1984).
27. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin re-uptake inhibitors. J. Neuropsychiatry Clin. Neurosci. 10, 453-455 (1998).
28. Mohr DC, Cox D, Epstein L, Boudewyn A. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J. Behav. Ther. Exp. Psychiatry 33, 39-47 (2002).
29. Davison K, Bagley CR. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: a review of the literature. In: Current Problems in Neuropsychiatry. Herrington FA (Ed.). Headly, Kent, UK, 113-184 (1969).
30. Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br. J. Psychiatry 161, 680-685 (1992).
31. Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol. Med. 19, 887-895 (1989).
32. Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. Arch. Neurol. 41, 1067-1069 (1984).
33. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects. Incidence, diagnosis and management. Drug Safety 22, 111-122 (2000).
34. Patten SB, Williams JVA, Petcu R, Oldfield R. Delirium in psychiatric in-patients. A case-control study. Can. J. Psychiatry 46, 162-166 (2001).
35. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis. Natural history, pathophysiology and management. CNS Drugs 16, 445-455 (2002).
36. Folstein MF, Folstein SE, McHugh PR. Mini-mental State Examination. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198 (1975).
37. Amato MP, Zipoli V. Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence. Int. MS J. 10, 72-83 (2003).
38. Plohmann AM, Kappos L, Ammann W et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 455-462 (1998).
39. Solari A, Motta A, Mendozzi L et al. Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. J. Neurol. Sci. 222, 99-104 (2004).
40. Krupp LB, Christodoulou C, Melville P et al. Donepezil improved memory in multiple sclerosis in a randomized controlled trial. Neurology 63, 1579-1585 (2004).
41. Geisler MW, Sliwinski M, Coyle PK et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neurol. 53, 185-188 (1996).
42. Lincoln NB, Dent A, Harding J et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 72, 93-98 (2001).
43. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis: 1. Frequency, patterns, and prediction. Can. J. Neurol. Sci. 21, 9-14 (1994).
44. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch. Phys. Med. Rehabil. 65, 135-138 (1984).
45. Zifko UA. Management of fatigue in patients with multiple sclerosis. Drug 64, 1295-1304 (2004).
46. Taus C, Solari A, D'Amico R et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews (2004).
47. Rossini PM, Pasqualetti P, Pozzilli C et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7, 354-358 (2001).
48. Krupp LB. Fatigue in multiple sclerosis. Definition, pathophysiology and treatment. CNS Drugs 17, 225-234 (2003).
49. Frierson RL, Wey JJ, Tabler JB. Psychostimulants for depression in the medically ill. Am. Family Physician 43, 163-170 (1991).
50. Krupp LB, Coyle PK, Doscher C et al. Fatigue therapy in multiple sclerosis: results of a double-bind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 45, 1956-1961 (1995).
51. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 249, 983-987 (2002).
52. Rammohan KW, Rosenberg JH, Lynn DJ et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. J. Neurol. Neurosurg. Psychiatry 72, 179-183 (2002).
53. Pliskin NH, Hamer DP, Goldstein DS et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving Interferon β-1b. Neurology 47, 1463-1468 (1996).
54. Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of Interferon β-1a in relapsing multiple sclerosis. Ann. Neurol. 48, 885-892 (2000).
55. Freo U, Pizzolato G, Dam M, Ori C, Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J. Neural Transm. 109, 857-870 (2002).
56. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 18, 397-401 (2004).